Results 81 to 90 of about 32,832 (202)

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

, 2017
Fibroblast growth factor receptor (FGFR) genetic alterations are frequently observed in cancer, suggesting that FGFR inhibition may be a promising therapy in patients harboring these lesions. Identification of predictive and pharmacodynamic biomarkers to
Michael Sharp, Katherine Bell, Ademi Santiago-Walker, Feng R. Luo, Gabriela Martinez Cardona, Suso J. Platero, Jayaprakash D. Karkera, John D. Alvarez, Rastislav Bahleda, Peter King, Matthew V. Lorenzi, Joseph C. Portale, Christopher H. Moy, Dana Gaffney   +13 more
core   +1 more source

FGFR-gerichtete Therapie von Kopf-Hals-Karzinomen

, 2020
Background!#!Genomic aberrations (mutations, gene fusions, amplifications) and dysregulation of the fibroblast growth factor (FGF) receptor (FGFR) signaling pathway are frequently found in squamous cell carcinomas of the head and neck (HNSCCs).
Dietrich, Dimo
core   +1 more source

ARQ 087 inhibits FGFR phosphorylation.

, 2016
COS-1 cells ectopically expressing FGFR1, FGFR2, FGFR3 or FGFR4 were treated with the indicated concentrations of ARQ 087 for 2 hours followed by stimulation with 100 pM of FGF1/2/7 for 15 minutes.
Jean-Marc Lapierre (2861762), Ronald E. Savage (813914), Yi Yu (28902), Sudharshan Eathiraj (813915), Brian Schwartz (767427), Terence G. Hall (3119784), Giovanni Abbadessa (486595), Yunxia Wang (294320)   +7 more
core   +1 more source

Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1

, 1994
We have studied the signal transduction pathways of fibroblast growth factor receptor-4 (FGFR-4) and FGFR-1, which showed virtually identical acidic fibroblast growth factor binding profiles as well as tyrosine autophosphorylation upon activation in ...
S. Wennström, K. Alitalo, P. G. Pelicci, M. Bergman, S. Vainikka, V. Joukov   +5 more
core  

Absolute quantitation of FGFR-2-IIIb and FGFR-2-IIIc mRNA in thyroid samples by Real-Time PCR.

, 2013
Absolute quantitation of FGFR-2-IIIb and FGFR-2-IIIc mRNA in thyroid samples by Real-Time PCR.
Giorgio Di Rocco (382578), Adriano Redler (296895), Sirio D’Amici (403067), Simona Ceccarelli (49503), Maria Giulia Bernieri (447464), Cinzia Marchese (49506), Enrica Vescarelli (403068), Francesca Frezzotti (447463), Anna Paola Mitterhofer (447465), Antonio Angeloni (49507), Domenico Giannotti (382576)   +10 more
core   +1 more source

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR

, 2020
SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2.
Le, Thi Bich Uyen, Mohseni, Mori, Lu, Henry, Liu, Chen, Engelman, Jeffrey, Caponigro, Giordano, LaMarche, Matthew, Hammerman, Peter, Hao, Huaixiang, Huynh, Hung   +9 more
core   +1 more source

Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

, 2023
IC50 values of Ba/F3 cells harboring FGFR3:TACC3 mutants exposed to eight selective FGFR inhibitors.
Rastislav Bahleda (16617234), Giorgia Guaitoli (16827105), Francesco Facchinetti (16827090), David Combarel (16827111), Stefan Michiels (9081965), Antoine Hollebecque (15010338), Yoann Pradat (15352227), Santiago Ponce-Aix (16827114), Sergey I. Nikolaev (15061686), Luc Friboulet (15025943), Lambros Tselikas (15019536), Ludovic Bigot (16617254), Juan David Florez Arango (16827102), Hayato Mizuta (16827108), Benjamin Besse (15061674), Damien Vasseur (16827096), Cédric Pobel (16617263), Olivier Déas (16827099), Floriane Braye (16827093), Ken A. Olaussen (16827117), Yohann Loriot (15123021), Jean-Yves Scoazec (15036392)   +21 more
core   +1 more source

Future applications of FGF/FGFR inhibitors in cancer

, 2018
Deregulation of the fibroblast growth factor (FGF)/FGF receptor (FGFR) network occurs frequently in tumors due to gene amplification, activating mutations, and oncogenic fusions.
GHEDINI, Gaia Cristina, Marco Presta, Arianna Giacomini, Ronca roberto   +3 more
core   +1 more source

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

, 2013
Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer.
Roychowdhury, Sameek, Sadis, Seth, Hussain, Maha H., Robinson, Dan R., Kalyana-Sundaram, Shanker, Feng, Felix Y., Khazanov, Nickolay, Siddiqui, Javed, Wyngaard, Peter, Pienta, Kenneth J., Lin, Su-Fang, Vats, Pankaj, Cao, Xuhong, Kunju, Lakshmi P., Ateeq, Bushra, Wu, Yi-Mi, Lonigro, Robert J., Zalupski, Mark M., Su, Fengyun, Wang, Rui, Chinnaiyan, Arul M., Talpaz, Moshe, Tomlins, Scott A., Rhodes, Daniel R., Cheng, Ann-Joy   +24 more
core   +2 more sources

Advances and challenges in targeting FGFR signalling in cancer

, 2016
Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential therapeutic target supported ...
Irina S. Babina, Nicholas C. Turner, Turner, NC, Babina, IS   +3 more
core   +1 more source